Background-Proper development of compact myocardium, coronary vessels, and Purkinje fibers depends on the presence of epicardium-derived cells (EPDCs) in embryonic myocardium. We hypothesized that adult human EPDCs might partly reactivate their embryonic program when transplanted into ischemic myocardium and improve cardiac performance after myocardial infarction. Methods and Results-EPDCs were isolated from human adult atrial tissue. Myocardial infarction was created in immunodeficient mice, followed by intramyocardial injection of 4ϫ10 5 enhanced green fluorescent protein-labeled EPDCs (2-week survival, nϭ22; 6-week survival, nϭ15) or culture medium (nϭ24 and nϭ18, respectively). Left ventricular function was assessed with a 9.4T animal MRI unit. Ejection fraction was similar between groups on day 2 but was significantly higher in the EPDC-injected group at 2 weeks (short term), as well as after long-term survival at 6 weeks. End-systolic and end-diastolic volumes were significantly smaller in the EPDC-injected group than in the medium-injected group at all ages evaluated. At 2 weeks, vascularization was significantly increased in the EPDC-treated group, as was wall thickness, a development that might be explained by augmented DNA-damage repair activity in the infarcted area. Immunohistochemical analysis showed massive engraftment of injected EPDCs at 2 weeks, with expression of ␣-smooth muscle actin, von Willebrand factor, sarcoplasmic reticulum Ca 2ϩ -ATPase, and voltage-gated sodium channel (␣-subunit; SCN5a). EPDCs were negative for cardiomyocyte markers. At 6-weeks survival, wall thickness was still increased, but only a few EPDCs could be detected. 
C urrent therapy aimed at alleviating the sequelae of sustained myocardial infarction (MI) is not able to restore the function of the scarred area. Stem cell therapy poses a promising alternative therapy. Because therapeutic use of embryonic stem cells is an ethically intricate issue and is technically difficult in relation to the possible rejection of the cells and tumor formation, use of adult stem cells appears to be a more feasible option. Many different types of adult cells have been demonstrated to improve cardiac function after a MI, although the underlying mechanism has only been partially unraveled (for review, see Murry et al 1 ) . Most of the cell types used are not known to be of importance during normal cardiogenesis. We chose to transplant epicardiumderived cells (EPDCs) because these cells are known to be crucial for cardiac development, because of both their physical contribution 2 and their modulatory role. 3, 4 
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During embryogenesis, epicardium migrates from the extracardiac proepicardium to cover the premature heart, which by that time consists of only myocardium and endocardium, with cardiac jelly in between. 5 A subset of the epicardial cells undergoes epithelial-mesenchymal transformation (EMT). These cells are called EPDCs. 2 EPDCs migrate into the myocardium to differentiate into interstitial cardiac fibroblasts, subendocardial and atrioventricular cushion mesenchymal cells, and coronary smooth muscle cells and adventitial fibroblasts. 2,6 -8 In addition to this physical contribution of EPDCs to the coronary vessels and the fibrous heart skeleton, EPDCs have a modulatory role in cardiogenesis. 9, 10 Formation of the compact myocardium, 3, 4 coronary vessel formation, [11] [12] [13] and Purkinje fiber cell differentiation 2, 14 are dependent on EPDC regulation. If epicardial outgrowth is inhibited completely, the myocardium remains thin, and normal septation does not take place, which leads to early embryonic death. 3 In addition to hampered formation of the compact myocardium, vascular development is severely disturbed in partial epicardial abrogation. 11, 15 The role of EPDCs during postnatal cardiac growth has never been elucidated. It is unknown whether new EPDCs are generated continuously through EMT, contributing to the growing structures of the heart and regulating developmental processes. It has been shown, however, that adult rat epicardial cells are at least still able to undergo EMT and differentiate into smooth muscle cells in vitro. 16 We recently demonstrated that adult human cells derived from epicardial explants (hEPDCs) can undergo EMT spontaneously, as observed by a transformation from cobblestone into spindleshaped morphology, while losing their ␤-catenin expression. 17 In the present study, we also used Wilms' tumor 1 suppressor protein (WT1) expression to investigate this aspect. During cardiogenesis, expression of WT1 is observed in the proepicardium and the epicardial cells but is lost in the EPDCs soon after they have undergone EMT. 18, 19 Furthermore, it has been shown that adult epicardial cells positively modify cardiomyocyte phenotype and function 20 and that WT1 is switched on de novo in adult coronary vessels in ischemic myocardium. 21 Being relatively undifferentiated cells that can give rise to differentiated progeny of at least smooth muscle cells and fibroblasts, embryonic EPDCs have been referred to as stem cells. 22 Given that adult hEPDCs can still undergo EMT and can give rise to the above-mentioned cell types, 17 we consider adult hEPDCs as progenitor cells. We hypothesized that adult hEPDCs could recapitulate part of their embryonic program when transplanted into diseased myocardium, thereby positively modifying the surrounding myocardium.
In the present study, we investigated in a mouse model whether adult hEPDCs could improve cardiac performance after MI. Adult spindle-shaped hEPDCs were transplanted into ischemic murine myocardium. Evaluation of this population revealed that these cells showed no expression pattern indicative of endothelial cells or cardiomyocytes. 17 
Methods
See the online Data Supplement for an expanded Methods section.
Primary Cultured hEPDCs
EPDCs were cultured from human adult epicardium, which was separated mechanically from atrial appendages. Spindle-shaped cells (see Data Supplement Figure I ) from passages 2 to 4 were used for transplantation experiments after transduction with a human vector expressing the enhanced green fluorescent protein (eGFP) gene, which enabled cell tracing. An adenoviral and a lentiviral vector were used for short-term (2-week survival) and long-term (6-week survival) experiments, respectively.
Creation of the MI and Cell Transplantation
To avoid rejection of transplanted human cells, nonobese diabeticsevere combined immunodeficient (NOD/scid) mice were used. 23 All animal procedures were approved by the Animal Ethics Committee of Leiden University and conformed to the Guide for the Care and Use of Laboratory Animals (National Institutes of Health publication No. 85-23, revised 1996). For short-term experiments, the main left anterior descending coronary artery was permanently ligated. For long-term experiments, only the branch supplying the ventral wall of the left ventricle (LV) was ligated, because extended survival until 6 weeks is not possible with the entire LV infarcted. Immediately after ligation, transplantation of 4ϫ10 5 hEPDCs suspended in M199 (hEPDC group; 2-week survival, nϭ22; 6-week survival, nϭ15) or cell-free M199 (medium group; 2-week survival, nϭ24; 6-week survival, nϭ18) was performed into the ischemic myocardium. Sham-operated animals (2-week survival, nϭ16; 6-week survival, nϭ3) were operated on similarly but without ligation of the main left anterior descending coronary artery and without fluid injection. Animals were randomized to treatment.
Short-Term Experiments

Magnetic Resonance Imaging
Infarct size (2 days after surgery) and cardiac function (2 and 14 days after surgery) were assessed with contrast-enhanced and cine MRI images (9.4T). Images were analyzed by manual delineation of endocardial and epicardial borders (hEPDC group, nϭ17; medium group, nϭ14; sham group, nϭ13) with dedicated software (see Data Supplement for detailed information). LV infarcted area, end-diastolic volume (EDV), end-systolic volume (ESV), stroke volume (SV), and ejection fraction (EF) were computed automatically. 24 Infarct area measurements were used to correct functional parameters for potential differences in initial infarct size.
Immunohistochemical Assessment
Animals were euthanized 15 days after surgery. Paraffin sections of the hearts (nϭ5 per group) were used for immunohistochemical analysis. To investigate host tissue properties, serial sections were stained for CD31, ␣/␥-muscle actin, ␣-smooth muscle actin, proliferating cell nuclear antigen (PCNA), phosphohistone H3, and phosphohistone H2AX. Nonfluorescent anti-eGFP staining was performed to visualize the injected hEPDCs because the strong and irregular autofluorescence of the heart disturbs assessment of spontaneous eGFP fluorescence to detect engrafted cells.
To identify which proteins were expressed by the injected hEPDCs, double stainings were performed for eGFP and other proteins, including ␣-smooth muscle actin, von Willebrand factor (vWF), sarcoplasmic or endoplasmic reticulum Ca 2ϩ -ATPase (SERCA2a), voltage-gated sodium channel (␣-subunit; SCN5a), cardiac troponin I, atrial natriuretic peptide, ␣/␥-muscle actin (clone HHF35), and sarcomeric myosin (clone MF20). A red Qdot conjugated goat anti-rabbit antibody was used to visualize eGFP staining. An appropriate biotinylated secondary antibody in combination with yellow Qdot conjugated to streptavidin was used to visualize the other proteins. For details, see the Data Supplement.
LV Vascular Profile and Wall Thickness
To evaluate the angiogenic effect of hEPDC transplantation, the cumulative area of CD31-stained vessel lining per total LV area was determined in the hEPDC and medium group (nϭ5 for each group). LV wall thickness was measured in the hearts of the hEPDC and medium group (nϭ5 for each group) by an observer blinded to treatment. Wall thickness was measured in both border zones of the infarcted wall, in the mid-infarcted area between the border zones, and in the middle of the interventricular septum.
General Health and Survival
Body weight was determined just before surgery at day 0 and before euthanasia at day 15. Pulmonary water content was estimated after euthanasia by subtracting dry weight from wet weight of the lungs. To correct for differences in body mass, the amount of lung fluid was expressed relative to body weight. Survival proportions were assessed.
Long-Term Experiments
Magnetic Resonance Imaging
The effect of hEPDC transplantation in the long term was evaluated by cine MRI images 42 days after surgery only (hEPDC group, nϭ15; medium group, nϭ14; sham group, nϭ3) because of the high risk of mortality during repeated imaging procedures.
Immunohistochemical Assessment
Animals were euthanized 43 days after surgery. Excised hearts were treated as described for short-term experiments, except for 3 hearts in the medium and hEPDC groups that were frozen. To identify injected cells, nonfluorescent stainings were performed in paraffin sections for eGFP, human-specific CD31, and human-specific vWF and in frozen sections for human nucleus.
LV Vascular Profile and Wall Thickness
Anti-CD31 and Sirius red staining and wall thickness measurements were used for host tissue investigation.
Survival
Survival proportions were assessed.
Statistical Analysis
Data are presented as meanϮSEM. Data were analyzed with SPSS software (SPSS Inc, Chicago, Ill). For comparisons of more than 2 groups, a 1-way-ANOVA was performed (or the nonparametric Kruskal-Wallis test for the dependent variable lung weight). If the omnibus tests among groups were significantly different, post hoc tests between groups with t tests (and Mann-Whitney test for lung weight) were performed. Infarct size was used as a covariate in an ANOVA/ANCOVA of the functional data to correct for baseline differences in infarct size among groups. Differences in mortality were evaluated with the Breslow test. A level of PϽ0.05 was considered to represent a significant difference.
The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.
Results
Cultured Adult hEPDCs
Within a few days, hEPDCs migrated from the epicardium dissected from the atrial appendages. In the first passage, mainly cobblestone and a few spindle-shaped cells were observed, whereas after 2 passages, all cells had adopted a spindle-shaped morphology (with loss of WT1 expression; Data Supplement Figure I ). Cells could easily be kept in culture, with a constant doubling time between day 10 and day 50, after which they went into senescence ( Figure 1 ). For a more extensive characterization of in vitro cultured hEPDCs, see Van Tuyn et al. 17 
Short-Term Experiments
LV Function
LV EF and SV decreased significantly after onset of MI. LV EF and SV were similar in the medium-and hEPDC-treated groups 2 days after surgery. However, at 14 days after surgery, significantly greater LV EF and SV were observed in the hEPDC-treated group than in the medium-treated group (Figure 2a and 2b) . LV EDV and LV ESV were significantly smaller in the hEPDC-treated group than in the mediumtreated group, both at 2 and 14 days after surgery (Figure 2c and 2d). Both medium-and hEPDC-treated mice showed heart-function parameters that differed significantly from the sham-operated animals. However, with respect to EDV on day 2 and SV on day 14, the hEPDC-treated group resembled the sham-operated group (Figure 2a through 2d) .
LV Wall Structure
Histological evaluation showed that at day 15, transplanted hEPDCs had engrafted mainly in the ischemic LV wall and formed layers of cells (Figure 3a and 3b) . Transplanted hEPDCs were not found in the lining of the coronary vessel wall (Figure 4a and 4b) .
The infarcted host tissue only showed the remaining cardiomyocytes in the subendocardial and, to a lesser extent, subepicardial position, which was not different between the hEPDC and medium groups (Figure 3c and 3d) . The cardiomyocytes and the intermediate fibrous wall tissue were negative for ␣-smooth muscle actin (Figure 3e and 3f) . Nuclear PCNA expression was increased in the infarcted LV wall (Figure 3g ) and the border zone (Figure 3h ) of the hEPDC group compared with the medium group (Figure 3i and 3j). DNA damage was present in these areas of both the medium and hEPDC groups, as demonstrated by phosphohistone H2AX staining (not shown). Phosphohistone H3 staining revealed that the low number of mitotic figures was not different between groups (not shown).
Hearts from the hEPDC group showed a complex vascular network that consisted of capillaries, veins, and arterioles with a high vascular density throughout the ischemic area (Figure 4c ) but that lacked the distribution of fine capillaries observed in healthy myocardium (Figure 4e ). Mediuminjected infarcted hearts were poorly vascularized, with small capillaries unequally dispersed throughout the ventricular wall (Figure 4d ). When determined quantitatively, free-wall endothelial density, expressed relative to septal endothelial density, was significantly higher in all parts of the LV of the hEPDC group than in the medium group (Figure 4f and 4g ). Wall thickness of the infarcted LV wall, the border zone, and the interventricular septum was significantly greater in the hEPDC-treated group than in the medium-treated group (Figure 4h) .
By double-staining techniques, we were able to investigate a number of differentiation markers in the engrafted hEPDCs. Almost all hEPDCs expressed ␣-smooth muscle actin (Figure 5a through 5c) and vWF (Figure 5d through 5f) . A number of hEPDCs were positive for SERCA2a and SCN5a (Figure 5g  through 5l) . The transplanted cells did not express the (cardio)myocyte markers atrial natriuretic peptide, cardiac troponin I, sarcomeric myosin, or ␣/␥-muscle actin (not shown).
General Health and Survival
Only a minor decrease in body weight between the day of surgery and the day of euthanasia (day 15) was observed in the hEPDC-treated group (Ϫ0.5Ϯ0.6 g), which was not statistically different from that in the sham-operated group (0.1Ϯ0.3 g). In contrast, the decrease in body weight was significantly larger in the medium-treated group (Ϫ2.7Ϯ1.0 g) than in the sham-operated group or the hEPDC-treated group (Figure 6a) . The decrease in body mass relative to the original weight amounted to 10Ϯ4% in the medium group, 2Ϯ2% in the hEPDC group, and 0Ϯ1% in the sham group.
Similarly, no significant difference at day 15 in the amount of lung fluid, corrected for body weight, was observed between the sham-operated and hEPDC-treated group, whereas lung edema was present in the medium-treated group (Figure 6b) .
Cumulative survival of medium-treated mice over the 2-week time period was significantly lower than that of the sham- 
Long-Term Effect of hEPDC Transplantation
The effect of hEPDC transplantation on cardiac function 6 weeks after MI was investigated in separate experiments. LV EF and SV were significantly greater 6 weeks after creation of MI in the hEPDC group than in the medium-treated group (Figure 8a and 8b) . Similarly, LV EDV and ESV were significantly smaller in the hEPDC group than in the medium group (Figure 8c and 8d) . Sham-operated animals showed values for these functional parameters that were all significantly different from those of the medium-and hEPDCtreated animals, except for SV (Figure 8a through 8d) . No deaths were observed in the hEPDC or sham group, in contrast to 4 deaths in the medium group (Figure 8e) .
Anti-eGFP staining only demonstrated a few engrafted hEPDCs, which were not embedded in the vessel lining (Figure 8f and 8g) . No cells positive for human-specific CD31 or vWF were observed in sections consecutive to the eGFP-stained sections. In the frozen sections of the hEPDC group, no cells were detected that stained positive for human nucleus (not shown).
Wall thickness of infarcted area and border zone was increased in the hEPDC group compared with the medium group (Figure 8h) . Properties of the scar itself were not significantly different between hEPDC-and medium-treated animals. The remaining cardiomyocytes observed in the scar area at week 2 had disappeared. The infarcted area in both groups consisted mainly of fibrous tissue (Figure 8i) , with many vessels situated in the border zone (Figure 8j ) and few vessels in the scar area (Figure 8k ).
Discussion
The main findings of the present study are that adult human EPDCs (1) can be isolated and cultured, during which they (arrowheads; b) . Endothelial CD31 staining in the LV wall shows a high vascular density and a complex vascular network that consists of small capillaries (arrowheads) and irregularly shaped large vessels (arrows) in the hEPDC group (c), which are lacking in the medium group (d). These profiles are very different from the capillaryrich myocardium in the sham-operated group (e). Quantification of endothelial density (expressed relative to septal values [dotted areas in f]) demonstrated a significantly higher degree of vascularization in all parts of the LV, represented by numbers 1 to 6 (f), in the hEPDC group than in the medium group (g). Wall thickness of the border zone, infarcted area, and interventricular septum was significantly greater in the hEPDC group than in the medium group (h). This difference is also visible in the pictures showing the LV wall of the hEPDC group (c) and medium group (d). Data are meanϮSEM. *PϽ0.05 vs medium group. RV indicates right ventricle; END, endocardium; and EP, epicardium. Scale bars in a through eϭ200 m; scale bar in fϭ400 m. undergo EMT; (2) engraft and survive in ischemic murine myocardium for at least 2 weeks, whereas only a few cells can be detected at 6 weeks; and (3) preserve LV function and attenuate postischemic remodeling until 6 weeks after MI. Embryonic EPDCs are known to be of crucial importance during cardiogenesis. They are essential for proper myocardial architecture and coronary vessel formation, both through their physical contribution and through regulation of these developmental processes. 2, 3, 10 Little is known about the role of adult EPDCs in the normal and diseased adult heart. We describe for the first time the use of adult hEPDCs, cells grown from human adult epicardial explants after EMT, 17 in cardiac regeneration therapy, applying them to possibly trigger embryological developmental processes that might restore or preserve cardiac function.
Immunologic Characterization of hEPDCs In Vivo
After 2 weeks, many hEPDCs were observed in the LV wall. They expressed the smooth muscle cell marker ␣-smooth muscle actin. This is in line with the fact that embryonic EPDCs express this protein when they differentiate into coronary smooth muscle cells, in addition to interstitial and adventitial coronary fibroblasts. 2 The ␣-smooth muscle actinpositive hEPDCs were not observed in the vessel wall but as isolated cells located in the scar tissue, having a shape similar to that of the surrounding fibroblasts. Part of the engrafted hEPDCs also expressed the marker SERCA2a, which is expressed in smooth muscle cells, skeletal muscle cells, and cardiomyocytes. 25 Staining for ␣/␥-muscle actin (clone HHF35), normally expressed by almost all muscle cells, 26 was negative in transplanted hEPDCs, which suggests that engrafted cells did not fully differentiate into a smooth muscle cell phenotype.
The injected hEPDCs did not acquire a cardiomyocyte phenotype, because the engrafted hEPDCs did not express the cardiomyocyte markers atrial natriuretic peptide, sarcomeric myosin, or cardiac troponin I. This is consistent with the finding that EPDCs do not differentiate into cardiomyocytes during embryonic heart development. 2, 6 Remarkably, immunostaining for SCN5a was positive in some engrafted hEP- DCs. SCN5a is mainly expressed in cardiomyocytes and has recently also been described in human gastrointestinal smooth muscle. 27 Therefore, we consider the expression pattern of the transplanted hEPDCs as that of a smooth muscle cell with extraordinary features, such as SCN5a expression.
Although the engrafted cells did not integrate into the vessel wall, a large portion of them were positive for the endothelial cell marker vWF at 2 weeks after MI. It is interesting that the engrafted adult hEPDCs expressed vWF, because the possible contribution of embryonic EPDCs to coronary endothelium is still a subject of debate. 13, 28, 29 Relevant to these findings are reports describing that endothelial markers can also be expressed by nonendothelial cells, such as certain skeletal muscle cells. 30 The expression profile of cultured hEPDCs in vitro is different from that of engrafted hEPDCs in vivo. Whereas engrafted hEPDCs in vivo stained positive for ␣-smooth muscle actin, vWF, SERCA2a, and SCN5a proteins, hEPDCs in vitro contained only ␣-smooth muscle actin mRNA, and mRNA for SCN5a and SERCA2a was not observed. Moreover, vWF staining was negative in cultured hEPDCs in vitro. 17 This implies that the expression pattern of hEPDCs changes in reaction to the surrounding ischemic tissue, which results in relatively undifferentiated engrafted cells with a myoendothelial phenotype. 30 The engraftment of the hEPDCs is temporary, because only a few hEPDCs could be detected at week 6. These cells did not express vWF, which indicates that the myoendothelial phenotype is at least partly transitional.
Histological Characteristics of the Surrounding Host Tissue
High vascular densities were observed in all parts of the LV wall of hEPDC-injected hearts 2 weeks after MI. The highly organized vascular network in the host tissue of the hEPDC group consisted of variably sized but mainly large-diameter vessels, whereas the medium group contained only a few vessels that were spread irregularly throughout the ischemic area. However, the high density of capillaries observed in healthy myocardium was lacking in the hEPDC group. The vessels must have been of murine origin, because no hEPDCs were observed to be integrated in the vessel lining, a finding confirmed at 6 weeks' survival. It remains to be investigated whether more vessels had survived or new murine (host) vessels were formed after hEPDC injection. An indirect paracrine stimulatory effect of hEPDCs on vessel survival or angiogenesis is suggested, because (1) hEPDCs were not found in vessel linings, and (2) vessels were found throughout the entire LV wall of the hEPDC group, not just in areas with a high density of engrafted hEPDCs. At week 6, differences in vascular profiling had disappeared, which suggests a transitional effect of hEPDCs on the vessels.
The increased PCNA expression in the infarcted area and border zone of the hEPDC group compared with the medium group might explain in part the significantly increased wall thickness in these areas of the hEPDC group, both early and late after MI. PCNA is a central protein in both replication and DNA-damage repair. [31] [32] [33] Because phosphohistone H3 staining revealed only a few mitotic figures, which was not different between groups, it is likely that the PCNA-positive cells represent cells with DNA-damage repair rather than proliferating cells. This was supported by the fact that DNA damage was indeed present in both groups. Increased cellular survival 34 due to augmented repair might then have contributed to a thicker wall. Further research, however, is needed to unravel the processes that underlie the increased PCNA activity and to determine whether the PCNA-positive cells are indeed repairing DNA damage or whether they represent activated and proliferating cells as well.
On the other hand, diminished ventricular dilatation itself, 35 as well as increased proliferation of cardiac stem cells 36 and other host tissue cells immediately after MI (before day 14), might have affected wall thickness. 34, [37] [38] [39] It seems unlikely that new cardiomyocyte formation 40 contributed to the increment in wall thickness in the hEPDC group, because the cardiomyocytes observed in the subendocardial and subepicardial regions of the infarcted area of the hEPDC and medium group were negative for ␣-smooth muscle actin, which is normally expressed by primitive but not by adult cardiomyocytes. 41 Moreover, whereas wall thickness at week 6 was still increased in the hEPDC-treated hearts, hardly any cardiomyocytes were observed in the ischemic area.
Functional Improvement
Main left anterior descending coronary artery occlusion results in MIs that vary in size, with associated variability in ventricular volumes. 42 To discern possible treatment effects, it appears mandatory to determine the initial infarct size and to correct functional data for any differences in infarct size. We performed this step by assessing infarct size with contrast-enhanced MRI images and subsequent covariance analysis of functional parameters. 43 Functional data were acquired by MRI, which is considered to be the "gold standard" for ventricular function assessment in small animals, 44 creating high-resolution images, especially at 9.4T. In contrast to 1D or 2D echocardiography and conductance catheter measurements, computation of ventricular volumes from MRI images is not based on specific geometric assumptions but on real data, which makes it a reliable method for determination of infarcted, abnormally shaped hearts.
We showed that hEPDC transplantation in the acutely infarcted myocardium improved cardiac function 2 weeks Figure 8 . Results of hEPDC transplantation 6 weeks after MI. EF (a) and SV (b) were significantly higher in the hEPDCinjected group 6 weeks after MI. hEPDC transplantation resulted in significantly smaller EDV (c) and ESV (d) than with medium injection. A better survival was observed in the hEPDC group than in the medium group (Pϭ0.057; e). Only a few eGFP-positive hEPDCs (brown) were detected in the hearts 6 weeks after hEPDC transplantation, mainly in the border zone (f, g). hEPDCs (arrows) did not integrate in the vessel lining (g). Wall thickness of the infarcted area and the border zone was significantly higher in the hEPDC group than in the medium group 6 weeks after MI (h). i, j, and k are from hEPDC-treated hearts but are also representative of medium-treated hearts. Sirius red staining demonstrates that the infarcted area consisted of mainly fibrous tissue (i). Many vessels could be observed in the border zone (j), whereas hardly any vessels were found in the infarcted area (k). Data are meanϮSEM. *PϽ0.05. RV indicates right ventricle; END, endocardium; EP, epicardium; a, artery; v, vein. Scale bars in f and gϭ30 m; scale bar in iϭ600 m; scale bars in j and kϭ60 m.
after induction of MI. This improvement was represented by a higher EF, larger SV, and less lung edema in the hEPDC group than in medium-treated animals. Moreover, a smaller EDV in the hEPDC group demonstrated that ventricular remodeling was reduced by hEPDC transplantation. However, EDV was still 2-to 3-fold higher in the hEPDC group than in the sham group, which illustrates the fact that hEPDC transplantation does result in less deterioration or preservation of cardiac function, not in restoration of normal function. An early protective effect of the hEPDCs was indicated by the fact that a smaller LV EDV and ESV were observed as soon as 2 days after the onset of MI. It cannot be determined whether this early effect is responsible for the observed positive influence of hEPDC transplantation after several weeks. Studies in which hEPDCs are injected a few days after MI might reveal this contribution.
The increased survival proportions in the hEPDC group might be explained by the improved cardiac function and reduced ventricular remodeling, because LV dysfunction and mortality are highly correlated. 45 Animals in the hEPDC group did not show cardiac cachexia 2 weeks after MI, defined as weight loss Ͼ7.5% of the original weight, 46 which is known to be a severe complication of chronic heart failure and which is associated with a poor prognosis. Cardiac cachexia, however, was observed in the medium-treated group, which had a relative weight loss of 10%. Mice in the hEPDC group showed less lung edema than mice in the medium group, which illustrates that the absence of weight loss in the hEPDC group was not obscured by edema.
To investigate whether the beneficial effect of hEPDC transplantation on the infarcted heart remained until a definitive scar had been formed, an additional set of experiments was performed with analysis 6 weeks after MI. We demonstrated that EF and SV were still significantly higher in the hEPDC group than in the medium group. Moreover, ESV and EDV were again significantly smaller in the hEPDC-injected group, which demonstrates decreased remodeling 6 weeks after MI. The survival benefit for the hEPDC-treated group after 6 weeks confirmed the beneficial influence of hEPDC transplantation in the long term. These data suggest that the effect of hEPDCs on cardiac function is stable, although we still cannot exclude an early paracrine effect, as has been described for other stem cells. 34, 47 The exact mechanism underlying the improvement in cardiac function caused by hEPDC transplantation remains to be investigated. We suggest from the present data that the injected hEPDCs protect host tissue cells through augmented DNA-damage repair, which results in augmented cellular survival 34 and subsequent prevention of extreme wall thinning, which will contribute to preservation of LV function and reduced functional remodeling in both the short and long term. A paracrine effect of the transplanted cells on the host tissue is indicated, because functional data demonstrate an effect of the hEPDCs as early as day 2, and because histological data show differences between groups in host tissue properties rather than newly formed donor-derived tissue in the hEPDC group.
Clinical Relevance
We showed that adult hEPDCs grow easily in culture during several passages and acquire spindle-shaped morphology, similar to embryonic EPDCs that have undergone EMT, which enables migration into the myocardium. 2 Because they preserved cardiac function and reduced remodeling both early and late after the onset of MI, autologous EPDCs appear promising for use in cardiac regeneration therapy. Preferably, these cells should be injected intramyocardially, by use of the catheter-based methods described previously. 48 In the present study, atrial appendages were harvested during CABG procedures. For broader clinical applications, a minimally invasive cardiac surgical technique is to be preferred, such as endoscopic surgery. Atrial appendages are removed by this technique as therapy in atrial fibrillation. 49 Transplantation of autologous EPDCs will not generate ethical problems, and there will be little risk of rejection. This makes them ideal candidates for cell therapy. Spontaneous tumor formation is not an issue, because we demonstrated that adult hEPDCs do not divide indefinitely, nor did we observe any tumor formation in the ischemic mouse heart up to 6 weeks after transplantation. In a clinical setting, EPDCs can probably only be transplanted in the chronically infarcted, reperfused heart. We are currently studying this aspect.
